About the Company
Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $STRO News
Sutro Biopharma (STRO) Price Target Decreased by 6.45% to 13.15
The average one-year price target for Sutro Biopharma (NasdaqGM:STRO) has been revised to 13.15 / share. This is an decrease ...
Sutro Biopharma gets grant for hemiasterlin derivatives for treating cell proliferation and cancer
Discover the latest patent from Sutro Biopharma Inc for hemiasterlin derivatives in Formula 1000, offering innovative methods for treating cell proliferation and cancer. Explore the potential ...
Are Sutro Biopharma Inc (NASDAQ: STRO) Analysts Predicting A Spike?
Sutro Biopharma Inc (NASDAQ:STRO) shares, rose in value, without any change to the previous day’s close as strong demand from buyers drove the stock to $5.09. Actively observing the price movement in ...
Ipsen signs $1.8bn RNA drug alliance with Skyhawk
Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the ...
Deal watch: Biopharma M&A more than doubled in Q1
Mergers and acquisitions are on the rise in 2024, sending a hopeful sign for the recovery of the life sciences market. Check ...
GlycoMimetics gets grant for treatment and prevention of diseases by inhibiting E-selectin binding
Discover the groundbreaking patent by GlycoMimetics Inc for E-selectin antagonists, offering innovative methods for treating diseases like cancer and inflammatory conditions. Explore the potential of ...
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for ...
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals
Tarsus, a Californian biopharmaceutical company, currently markets its Xdemvy treatment for demodex blepharitis which in 2023 generated net sales of USD14.7 million. Alongside this, Tarsus is ...
Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases
Ipsen and Skyhawk Therapeutics collaborate to develop novel small molecules for rare neurological diseases, with potential for up to $1.8 billion ...
Xeris Biopharma Holdings Inc (XERS) Stock: What the Analysts are Saying
Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for XERS is 125.56M, and at present, short sellers hold a 7.16% ...
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PCVX), a clinical-stage vaccine innovation company ...
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
Bio-Rad BIO has been facing the impact of funding issues in the biopharmaceutical or BioPharma space, macroeconomic headwinds ...
Loading the latest forecasts...